ERBB2 and acute lymphoblastic leukemia: The effect of Rituximab was again significantly (p < 0.01) more pronounced than that of Trastuzumab, and a significant (p < 0.01) additive effect was observed with ALL cells expressing CD20 and HER2/neu upon application of both antibodies (Fig. 4c and 4d).